Dermatofibrosarcoma
📧 Sign up to get email alerts when something new happens for Dermatofibrosarcoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-05-06EMA Authorised: Imatinib Accord (imatinib) — Accord Healthcare S.L.U.
The EMA authorised Imatinib Accord (imatinib) for several indications, including Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibr…
-
EMA withdrawal · 2023-10-19EMA Withdrawn: Imatinib Koanaa (imatinib mesilate) — Koanaa Healthcare GmbH
The EMA status shows Imatinib Koanaa (imatinib mesilate) has been withdrawn from the market by Koanaa Healthcare GmbH.
-
EMA withdrawal · 2022-07-05EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf
EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, my…
-
EMA withdrawal · 2019-10-16EMA Withdrawn: Imatinib medac (imatinib) — Medac
The EMA has withdrawn Imatinib Medac (imatinib) from the market.
-
CLINICAL_TRIALS trial_result · 2018-12-27Clinical Trial Update: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors [Phase 1, Phase 2]
A pediatric Phase 1/2 study assessed the safety and early activity of weekly nab-paclitaxel in children with recurrent or refractory solid t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2018-10-09EMA Withdrawn: Imatinib Teva B.V. (imatinib mesilate) — Teva B.V.
EMA withdrew the Imatinib Teva B.V. product (imatinib mesilate) from the market.